Literature DB >> 10886218

Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).

B Fehse1, O Frerk, M Goldmann, M Bulduk, A R Zander.   

Abstract

T lymphocytes play an important role in allogeneic bone marrow/stem cell transplantation by supporting engraftment and immune recovery. Moreover, donor T cells have been shown to mediate the so-called graft-versus-leukaemia effect and are, therefore, increasingly used for adoptive immunotherapy. However, T-cell infusions are associated with the risk of a graft-versus-host reaction, which may lead to a life-threatening disease. To overcome this problem, we followed a new strategy for the exclusive depletion of alloreactive cells. We activated allogeneic T cells by cultivation on an adherent cell layer derived from peripheral blood. We then depleted activated cells based on the expression of CD25, CD69 or both activation-induced antigens using magnetic cell sorting. Mixed lymphocyte culture (MLC) reactions and helper T-lymphocyte precursor cell frequency (HTLP-f) assays demonstrated that this technique led to a significant decrease in alloreactivity of 'donor' cells, which at the same time preserved reactivity against third-party cells. The lowest level of alloreactivity was found when CD25 and CD69 antibodies were used together for depletion. This corresponds with our observation that expression of CD25 or CD69 may partially represent different activation pathways. We conclude that ex vivo depletion of CD25- and CD69-expressing alloreactive cells may help to overcome limitations of adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886218     DOI: 10.1046/j.1365-2141.2000.02074.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

2.  Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Authors:  Selim Kuçi; Eva Rettinger; Bernhard Voss; Gerrit Weber; Miriam Stais; Hermann Kreyenberg; Andre Willasch; Zyrafete Kuçi; Ewa Koscielniak; Stephan Klöss; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 3.  Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Tamara Tripic; Cliona M Rooney
Journal:  Expert Opin Biol Ther       Date:  2010-03       Impact factor: 4.388

4.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

5.  A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.

Authors:  Lin Yu; Xi Yang; Nan Huang; Qiao-Li Lang; Qi-Lin He; Wang Jian-Hua; Ge Liang-Peng
Journal:  Cancer Biol Ther       Date:  2020-04-02       Impact factor: 4.742

6.  Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Authors:  Osnat Bohana-Kashtan; Sebastien Morisot; Richard Hildreth; Cory Brayton; Hyam I Levitsky; Curt I Civin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

7.  Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation.

Authors:  Thea M Friedman; Kira Goldgirsh; Stephanie A Berger; Jenny Zilberberg; Joanne Filicko-O'Hara; Neal Flomenberg; Michele Donato; Scott D Rowley; Robert Korngold
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

8.  Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells.

Authors:  Pervinder Sagoo; Niwa Ali; Garima Garg; Frank O Nestle; Robert I Lechler; Giovanna Lombardi
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

9.  A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

Authors:  Stephan Mielke; Raquel Nunes; Katayoun Rezvani; Vicki S Fellowes; Annie Venne; Scott R Solomon; Yong Fan; Emma Gostick; David A Price; Christian Scotto; Elizabeth J Read; A John Barrett
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

Review 10.  Antiviral T-cell therapy.

Authors:  Ann M Leen; Helen E Heslop; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.